Tag: Announces
Wiley Announces About Face: The Essentials of Interaction Design, 4th Edition
Indianapolis, IN (PRWEB) September 16, 2014 The interaction design profession is thriving with the success of design-intensive companies, priming customers to expect “design” as a critical ingredient of marketplace success. Consumers have little tolerance for websites, apps and devices that don’t live up to their expectations, and the responding shift in business philosophy has become […]
Bookkeeper Girl Inc. Announces Partner Licensing and Nationwide Expansion
Denton, TX (PRWEB) September 15, 2014 Bookkeeper Girl Inc. – a leading online bookkeeping service located in Denton, TX – announced today that it is America’s newest (and possibly only!) partner-licensed, online bookkeeping service. Bookkeeper Girl, which was started six years ago by Kim Pollard with a laptop, a loyal client, and an idea of […]
Park Systems Announces Seminar on Nanoscale Characterization for Oil & Gas Industry in Houston TX on Oct 27 & 28, 2014
Houston, TX (PRWEB) September 04, 2014 Park Systems, a leading manufacturer of atomic force microscopy (AFM) products just announced they are sponsoring a complimentary Oil and Gas Industry AFM Imaging and Characterization Workshop that will be held in Houston Texas on Oct 27 & 28 at the Courtyard Marriott Medical Center, 7702 Main Street. Participants […]
DiaSorin Announces New Webinar in Their Annual Vitamin D Series
(PRWEB) August 28, 2014 DiaSorin has announced that their new webinar, “The Clinical Utility of 1,25 Dihydroxyvitamin D,” will feature guest speaker Dr. Gregory A. Plotnikoff, a physician and researcher at Penny George Institute for Health and Healing Integrative Medicine. Dr. Plotnikoff serves as an integrative medicine physician at the Penny George Institute for Health […]
Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). In an intent-to-treat (ITT) population, investigators […]